Background
Human immunodeficiency virus (HIV), a member of the
Retroviridae family in the genus of Lentivirus, is the main causing agent for severe immune suppression [
1,
2]. The disease severity is responsible for the development of a chronic, deadly condition, called acquired immunodeficiency syndrome or AIDS, which commits lifelong threats to the infected individuals [
3].
The employed existing antiretroviral therapies are showing promising results, but not enough for the complete eradication of HIV/AIDS [
4]. Although ARTs have reduced the viral load, transmission, and morbidity/mortality ratio to a great extent, their mechanism of action showed deleterious effects related to mtDNA, impaired glucose metabolism, hepatotoxicity, multidrug-resistant strains after prolonged periods of infection and upsurge of the reactive oxygen species (ROS) within the cell [
5‐
10]. Testing ethnomedicines and phytoconstituents for the development of anti-HIV potency like pharmaceuticals to overcome multidrug resistance, while at the same time, lacking in antioxidants is the need of the hour to meet the necessity of generating novel alternative treatments.
Studies have shown that plants are rich in secondary metabolites and phytochemicals like flavonoids, alkaloids, polyphenolics, sulphated polysaccharides, triterpenes, phenolics and coumarins. Moreover, phytoconstituent-based alternative medicines are cheaper, easily accessible, fewer side effects with better tolerance [
11,
12]. Natural bioactive compounds that could possess a distinct mode of action are not usually found in synthetic drugs [
13]. Various investigation has revealed the medicinal properties of phytotherapeutic plant
Carica papaya Linn. (
C. papaya) and
Psidium guajava (
P. guajava) as anti-virals, immunomodulatory, anti-inflammatory, antimicrobial, and antioxidant activity [
14,
15]. The polyphenol compound of these plants such as tocopherol, ascorbic acid, carotenoids, folic acid and flavonoids are the strong biochemical antioxidant components [
16]. Toxicological studies on mice and other animal models also showed no significant adverse effects, mutagenic, or aberrant effects of
C. papaya and
P. guajava [
17‐
20].
Notably, there is very limited research available on the distinctive constituents of C. papaya and P. guajava that have shown any antiviral effects. Therefore, the present study was designed to examine the chemical compositions, antiviral properties, and antioxidant activities of these two methanolic phyto-extracts. It is known that the interaction between ROS and HIV infection may represent a new approach to both prevention and treatment, however, the effect of the methanolic extract of C. papaya and P. guajava has not been investigated extensively in the anti-HIV-1 research. Therefore, the present study was undertaken to characterize the leaves extract of C. papaya and P. guajava to identify the presence of bioactive components and assess the effectiveness of these phyto-extracts against HIV-1 infection and their antioxidant properties at the cellular level. We conducted cellular assays to examine the effects of these two plants extracts upon the pathogenicity of HIV-1 strains, unveiled the underlying mechanisms, and determined its role as a free radical scavenger during HIV-1 infection. Hence, this study might divulge the role of leaves extract of C. papaya and P. guajava as dual antiviral and cytoprotective anti-oxidant agents that might be helpful in the development of an novel anti-HIV-1 therapy or in conjunction with the present ART regime.
Materials and methods
Plant collection for phyto-extract preparation
The collection of plant material was done after obtaining the necessary permission, purely for research purposes and it complies with international and institutional guidelines and legislation. Briefly, fresh and young leaves of
C. papaya and
P. guajava were collected from the local region of the city, near Sinhagad Road, Pune, India. The voucher specimens were formally identified and deposited at the Western Regional Centre, Botanical Survey of India (BSI), Pune, India (authentication no. DP01 for
C. papaya and NMPG-1 for
P. guajava). The leaves were primarily washed under tap water followed by distilled water to remove the dust particles. Further, the clean leaves were shaded, dried and pulverized followed by the methanol extract preparation as described earlier [
21]. Methanol is one of the effective solvents resulting in the highest extraction yield, and therefore used for examining various biological activities including anti-viral and anti-oxidant activity of different plant extracts as reported earlier [
22‐
25]. In this study, the 50 g of dried leaves powder of both plants was dissolved in 250 ml of 100% methanol, followed by incubation for 24 h at 150 rpm and 25 °C on a rotary shaker. After incubation, the mixture was allowed to stand for 10 min for the sedimentation and the supernatant was filtered through Whatman filter paper no. 1. The extracted samples were collected and placed on a rotary evaporator at 60 °C for methanol evaporation. The leaves extracts were then collected by protecting them from direct light and kept at 4 °C for further characterization and phytochemical analysis through High-resolution electrospray ionization mass spectrometry (HR-ESI–MS).
Phytochemical characterization and Identification of bioactive components from C. papaya and P. guajava leaves extract
Qualitative phytochemical tests were performed to check the presence of carbohydrates, flavonoids, saponins, tannins, terpenoids, cardiac glycosides, steroids, quinones and coumarins using standard protocols as described earlier by Shaikh and Patil, 2020 [
26]. The high throughput HR-ESI–MS technique was used in this study to identify the chemical constituent and bioactive compounds present in the leaves extract of
C. papaya and
P. guajava. Briefly, 1 mg extract was dissolved in 1.5 ml LC–MS grade methanol and clarified through a 0.2 μm filter membrane. Further 10μ/L was injected into the HR-MS column. The HR-ESI–MS analysis was carried out on an Agilent 6530 Q-TOF (Agilent, USA) mass spectrometer connected to an HPLC Prime Infinity II 1260 system (800 bar). A dual electrospray ionization (ESI) source was used for the ionization process. For LC-based metabolite separation, a Hypersil GOLD C18 (2.1 × 150 mm, 1.9 μm particle size, Thermo Scientific, USA) column was used at 40 °C with a flow rate of 0.3 ml/min. Silica gel (60 − 100 mesh and 100 − 200 mesh, Hi-media, India) was used for the chromatography column.
Cell lines and HIV-1 stock
TZM-bl cells (HeLa modified cell line; initially called JC53-bl; clone 13) were procured from the National Institute of Health (NIH)—HIV Reagent Program, and maintained in DMEM (Gibco, USA) containing 10% FBS (Moregate, Australia) and supplemented with HEPES (Gibco, USA), antibiotics (Sigma, USA) at 37 °C in a 5% CO2 humidified chamber.
The primary isolates of HIV-1UG070 (X4, Subtype D) and HIV-1VB028 (R5, Subtype C) were obtained from the virus bank repository maintained at the Division of Virology, ICMR-National AIDS Research Institute, Pune.
Cytotoxicity assay by MTT
Cytotoxic effect of both the plant extract
C. papaya and
P. guajava was performed in the TZM-bl cell line following the methods described earlier [
27,
28]. Briefly, 1 × 10
5 adherent TZM-bl cells/well were seeded on 96 well plate and incubated for 24 h supplied with 5% CO
2 at 37 °C. The purified phyto-extract dilutions were treated on the cell-seeded plates in dose dependent manner by taking an initial concentration of 6 mg/ml for
C. papaya and 8 mg/ml for
P. guajava, and incubated for 48 h. After the incubation period, the phyto-extracts were evaluated by adding 20 µl (5 mg/ml) MTT to all wells and further incubated for 3 h, which allows the MTT to get metabolized; the supernatant was replaced with 150 µl dimethyl sulfoxide (DMSO) to dissolve the formazan crystals. After the final incubation of an hour, the O.D. value was recorded at 550 nm and 630 nm using a multimode plate reader. The viability was observed based on a comparison with the absorbance of untreated and treated cells. The mean absorbance (O.D.) of duplicate wells was used to calculate the percentage of cell viability as follows: Percentage of cell viability = (Absorbance of Extract Treated Cells – Absorbance of Blank) / (Absorbance of Control – Absorbance of Blank) × 100%. The CC
50 was obtained at the concentration where 50% of the cells remain viable in presence of the phyto-extracts from three independent assays.
Cell associated assay (CA)
Based on the CC
50 value, a range of non-cytotoxic concentrations of the
C. papaya and
P. guajava extracts were used, and the anti-HIV-1 activity was evaluated as described previously [
28‐
31]. Briefly, the TZM-bl cells (1 × 10
4 cells/well) were first infected with the virus HIV-1
VB028 and HIV-1
UG070 for 2 h at 37 °C in 5% CO
2 incubator followed by the treatment with different dilutions of the extracts, along with the addition and incubation of 25 µg/ml DEAE-dextran for viral internalization. After 48 h post incubation, the luciferase activity was measured using the Britelite™ plus reagent on a luminometer (Perkin Elmer, USA) [
31,
32]. Standard nucleoside reverse transcriptase inhibitor drug Azidothymidine or AZT was used at the known concentration of 0.45 µM/ml for both the phyto-extracts, as a positive control.
Cell free assay (CF)
While in cell free assay (CF), the viral stocks were first treated with the serial dilutions of the
C. papaya and
P. guajava methanolic extracts and incubated for 1 h, at 37 °C in 5% CO
2 atmosphere preceding its addition on the TZM-bl cells (1 × 10
4 cells/well) [
28‐
30]. At 48 h post-infection, the luciferase activity was measured as described above. Dextran sulphate (DS) was used as a positive control for the cell-free assays at the known concentration of 15 µg/ml for both the phyto-extracts.
The percentage of HIV-1 inhibition and EC50 value for both CA and CF assays were calculated based on the activity of the respective phyto-extracts. The results were compared with the positive controls after carrying out all the experiments in triplicate.
Time-of-addition assay (TOA)
The Time-of-addition assay or TOA test was carried out as previously described with some modifications [
33]. The designed assay, which included the positive and negative controls, was quite similar to that utilized for measuring the inhibitory potencies through anti-HIV-1 assays. In 96-well plates, TZM-bl cells (1 × 10
4 cells/well) were seeded and after overnight incubation, the cells were infected with the HIV-1
VB028 strain at 400 TCID
50/ml. The inhibitors were either added to the wells concurrently (0hpi) or at different hours of post-infection as indicated (0.25-24hpi). At 48hpi the luciferase activity was assessed as described previously. The well-known anti-retrovirals Dextran sulphate (DS: Viral adsorption to the host cell inhibitor—15 µg/ml), Azidothymidine (AZT: An Nucleotide Reverse Transcriptase Inhibitors or NRTI—0.9 µM), Raltegravir (RAL: Integrase inhibitor—0.48 µM), Ritonavir (RTV: Protease inhibitor—45 µM), along with the
C. papaya (1.25 mg/ml) and
P. guajava (0.085 mg/ml) methanolic extract were employed in the experiment.
HIV-1 protease (PR) inhibition activity assay
The C. papaya and P. guajava extracts were tested for HIV-1 protease inhibitory activity using an HIV-1 PR inhibitor screening Fluorometric assay kit following the manufacturer's instructions (Abcam, Cambridge, UK). Briefly, each sample was incubated with the HIV-1 PR enzyme for 15 min at room temperature. The fluorescent substrate was then added, and the PerkinElmer EnSpire plate reader was used to measure the fluorescence (excitation/emission = 330/450 nm) in a kinetic mode for 120 min at 37 °C. The kit-supplied Inhibitor Control (IC) Pepstatin (1 mM) and known protease inhibitor RTV (45 µM) were used as the positive controls, whereas, DMSO (1%, v/v) and kit-supplied Enzyme Control (EC) were used as the vehicle and negative controls, respectively, to normalize the background noise.
Assessment of antioxidant activity
TZM-bl cells were seeded in 60 mm dishes at a density of 1 × 105 cells per plate and placed in an incubator for 24 h at 37 °C with 5% CO2. After incubation, the cells were infected with HIV-1VB028 and were treated with the respective phyto-extracts having concentration determined by their CC50 and EC50 values. At 24hpi, the cells were trypsinized, collected and centrifuged at 2000 rpm for 5 min and incubated with 5 µM DCF-DA green molecular probe at 37 °C incubator. At 30 min post-incubation, the cells were centrifuged again, washed and resuspended in PBS, followed by filtration through nylon mesh, and the acquisition was done using FACS Aria flow cytometer (BD Bioscience, USA). Flow Jo™ software was utilized to analyze the data. A total of 50,000 cells from each sample set were examined during the assay.
Free radical scavenging assay by DPPH method
DPPH (2,2-diphenyl-1-picryl-hydrazyl-hydrate) free radical method is an antioxidant assay based on electron transfer that produces a violet solution in ethanol [
34]. 50 µl of each phyto-extract (
C. papaya and
P. guajava), based on their respective EC
50, was added to a 96-well plate in triplicates. 100 µl of 0.2 mM of freshly prepared methanolic DPPH solution was added to the extracts, mixed, vortexed, and incubated on the 96-well plate at room temperature in a dark environment for 30 min. The absorbance was measured at 517 nm. Ascorbic acid was used as a standard and DPPH and methanol were taken as control. The DPPH scavenging effects were measured using the following formula: DPPH scavenging effect (%) = (A0 – A1/A0) × 100; where, A0 = Absorbance of Control; A1 = Absorbance of Sample.
Discussion
In this study, the biological activities of methanolic leaves extract from
Carica papaya Linn and
Psidium guajava were evaluated. The phytochemical profile of these two extracts were characterized by high throughput HR-ESI–MS analysis and revealed the presence of different bioactive constituents (Figs.
1 and
2; Table S
2 and S
3). The detailed in vitro studies indicated that both the leaves extract are less cytotoxic in nature (Fig.
3), with pronounced anti-HIV-1 activity (Figs.
4 and
5); while the TOA assay revealed the targets of action against HIV-1 (Fig.
6). In vitro enzymatic validation also confirmed the inhibitory role of
C. papaya extract against HIV-1 protease (Fig.
7). Additionally, the ROS scavenging activity of these phyto-extracts unveiled their antioxidant potential during HIV-1 infection (Fig.
8 and Table
1). Overall, the results indicate synergistic action of bioconstituents of
C. papaya and
P. guajava leaves extract lead to antiviral and antioxidant activity in HIV-1 infected cells.
In absence of non-toxic antiretroviral drug therapies, lack of vaccine, diversity in viral strains, and emergence of resistant viruses often led the researchers for continuous search of alternative antivirals and new lead molecules to prevent the deleterious effect of HIV-1 infection. Investigation on bioactive molecules from natural plant sources has been one of the best strategies for the treatment of various infectious diseases, including HIV-1. Natural products are therefore regaining appeal in drug development as they circumvent the limitations of synthetic libraries, such as their lack of chemical variety [
35]. Additionally, natural products have historically shown to be excellent starting points for the development of pharmaceuticals, with 34% of medications authorized by the FDA between 1981 and 2010 were from natural sources [
13]. Numerous active ingredients of natural products and their derivatives, including alkaloids, quinones, flavonoids, terpenoids, glycans, organic acids, and others, have antiviral action [
36]. According to a previous report, of all small-molecule drugs created in the last 28 years, 63.1% were natural product-based therapies [
13]. This number indicates the enormous potential for new medicine discovery offered by natural product and their derivatives.
C. papaya and
P. guajava represent an important source of phenolic compounds, some of which have been shown to have inhibitory effects against a number of viral infections [
37,
38]. In particular, terpene compositions were found to be effective against SARS-CoV-2 and alkaloids isolated in
I. indigotica roots were reported to reduce the influenza infection as well as the viral neuraminidase activities in vitro [
39‐
41]. Furthermore, alkaloids, phenolic compounds, and terpenes are known bioactive components that have been shown to have antioxidant properties and to have an influence on oxidative stress and related signalling pathways [
42‐
45].
In vitro viability testing has become an essential step in contemporary drug discovery, as it characterizes a compound's hazardous potential and gives proof of its safety index [
46,
47]. Hence, crude methanolic extracts of the fruit plant
Carica papaya Linn and
Psidium guajava were tested for cytotoxicity in the TZM-bl cell line using MTT-based cell viability assay. The crude extracts were found to be less cytotoxic to the cells, as exhibited by the CC
50 values, which were recorded as 2.07 and 1.84 mg/ml respectively for
C. papaya and
P. guajava in this study (Fig.
3 and Table
2), in accordance with the previous reports on other methanolic plant extracts those are already known to be low cytotoxic in nature [
48]. Effects of
C. papaya and
P. guajava have already been documented with no detectable side effects that could be considered harmful, mutagenic, or otherwise aberrant [
17‐
20].
Table 2
Summary of CC50, EC50 and SI of Carica papaya L and Psidium guajava leaf extracts
C. papaya L | 2.07 | 1.03 | 2.009 | 1.25 | 1.66 | 1.075 | 1.926 | 1.176 | 1.760 |
P. guajava | 1.84 | 0.07 | 26.28 | 0.085 | 21.65 | 0.073 | 25.21 | 0.054 | 34.07 |
Many studies have shown the potential of phyto-extracts against the HIV/AIDS. In a recent investigation it was observed that the methanolic extract of
Curcuma aeruginosa Roxb. plant suppressed the HIV-1 PR [
49]. Similar to this, another group of researchers reported the inhibition of HIV-1 encoded viral proteins by the bioactive from of
Alnus firma's methanol extract [
50]. Literature has revealed the medicinal properties of phytotherapic plants like
Carica papaya Linn and
Psidium guajava for their antiviral and antioxidant activity [
15]. In this brief study, we focused only on the anti-HIV-1 property and the antioxidant potential of
C. papaya and
P. guajava phyto-extract. The in vitro screening assays showed that both the extracts significantly inhibited the cell associated viral replication and cell free transmission of HIV-1 using two clinical isolates HIV-1
VB028 and HIV-1
UG070 from two different subtype of the virus (Figs.
4 and
5; Table
2). Additionally, Selectivity Index (SI) revealed that both the extracts mentioned above had variable activities. The
C. papaya extract demonstrated anti-HIV-1 activity against two different HIV-1 strains with SI values of 2.0 and 1.66 in cell associated assays, while cell free assays revealed SI values of 1.92 and 1.76 respectively. It's interesting to note that the SI index of
P. guajava revealed as 26.28 and 21.65 in cell associated assays and 25.21 to 34.07 in cells free assays (Table
2). These results suggest that the
P. guajava extract might act as more effective anti-HIV-1 agent over
C. papaya extract. Further we also carried out time-of-addition (TOA) experiment (Fig.
6). This TOA method determines how long a compound may be added to a cell culture without losing its antiviral properties. An antiviral compound's relative location in the time scale can be used to determine the target comparing to a reference drug. If the unknown drug's profile resembles with the existing known anti-HIV drug, it is highly likely that the unknown drug is targeting through the same route, or at the very least one that is active at the same time [
51].
P. guajava inhibition profile resembles dextran sulphate, which is an known inhibitor of viral entry and/or adsorption to the host cells. Earlier,
Cistus incanus extract was also demonstrated to inhibit a very early step in the HIV-1 replication cycle comparable to a fusion inhibitor [
33,
52]. In our experimental set up,
P. guajava showed pattern similar to Dextran Sulphate, while
C. papaya showed loss-of-inhibition profile similar to the HIV-1 protease inhibitor Ritonavir. Studies have revealed that any one molecule might have dual target, i.e., targeting two or more distinct phases of viral lifecycle by one such inhibitor, however the last target that can be blocked by the inhibitor during the viral replication will always be revealed by this experiment [
51]. As in this study, the resulting
P. guajava profile shows loss-of-inhibition at time points as observed for the entry and/or adsorption inhibitor DS, whereas, the loss of inhibition pattern and enzymatic validation confirmed the inhibitory role of
C. papaya extract against HIV-1 protease (Fig.
7).
The loss of immunological cells, especially CD4
+ T
H cells, is the defining feature of HIV-1 infection. According to the earlier study, the HIV-1 envelope glycoproteins are the prime cause for declined CD4
+ cells in the infected patients, which in turn trigger the accumulation of oxidative stress within the cells and leads towards the cell death [
53]. In this study, the DCFH
2-DA method was used to determine the HIV-1 induced ROS formation in the living cells, where the intensity of the fluorescence was associated with the measurement of generated ROS within the cells [
54]. The phyto-extracts treatment of
C. papaya and
P. guajava in the HIV-1 infected cells reduced the virus mediated ROS production significantly (Fig.
8). The reduction of ROS accumulation within the cells signifies the therapeutic effectiveness of these extracts as potential agents for the treatment of HIV-1 infection.
Recent studies have highlighted the manipulation of oxidative stress and antioxidant-dependent pathways to facilitate the novel strategies for HIV cure through preclinical in vitro studies and clinical trials [
31,
55‐
58]. There are ample evidences on improved status of HIV-1 infected patients with the treatment of antioxidants that enhances the glutathione levels while lowering the lipid peroxidation [
58]. The redox alterations is one of the crucial factors of HIV-1 pathogenicity, such as neurotoxicity and dementia, exhaustion of CD4
+/CD8
+ T-cells, predisposition to lung infections, and certain side effects of the antiretroviral therapy [
56]. Thus, anti-HIV-1 activity of any compound with antioxidant effects may offer a new strategy for prevention and treatment. Hence, maintaining the antioxidant level is an important parameter of HIV-1 patient management. According to the literature and the high throughput characterization carried out during this study revealed that both the plant extracts are the enriched source of antioxidants (Table S
2 and Table S
3), and nutraceutical value with multiple health benefits [
14,
15,
59,
60]. Although the involvement of the entire phyto-complex cannot be ruled out and perhaps the major limitation of this present study, our data indicates that the prime bioactive components, such as phenolic compounds, alkaloids, and terpenes, might be the key regulator of the antiviral effects of the
C. papaya and
P. guajava extracts. Together, these substances have the potential to affect both the virion life cycle and the host cells’ defense mechanism, primarily by reversing the redox imbalance, which is necessary for the viral infection to establish. However, the role of individual phytoconstituents on HIV-1 inhibition remains to be elucidated, in-depth mechanistic study would be the isolation of these phytoconstituents to unveil the plausible modus operandi. Overall, based on this study, it can be stated that the
Carica papaya Linn and
Psidium guajava plant extracts have anti-viral activity against HIV-1 with the anti-oxidant potential, hence need to be explored further.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.